Short answer
Regeneron Pharmaceuticals (REGN) filed an 8-K current report with the SEC on October 30, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Regeneron announced financial and operating results for the quarter ended September 30, 2026.
Regeneron Pharmaceuticals 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Regeneron announced financial and operating results for the quarter ended September 30, 2026
- Results press release furnished as Exhibit 99.1, providing the detailed figures and management commentary period investors should review
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $5.1B, up 36%, with non-GAAP EPS $20.07, up 70%, signaling strong operating momentum
- Sanofi collaboration revenue $2.724B, up 68%, after Development Balance repayment, improving recurring profit participation
- Expanded Sanofi alliance adds $1.0B upfront revenue in Q4 and potential milestones up to $7.0B
- EYLEA HD U.S. sales $699M, up 62%, offsetting legacy EYLEA sales decline of 41% to $400M
- 2026 guidance raised for R&D, gross margin and capital expenditures, while SG&A and tax-rate expectations improved
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Regeneron Pharmaceuticals 8-K filings
Get the next REGN 8-K as it lands
Follow REGN for push alerts, or ask the research agent what this filing means.